On March 16, 2021 AstraZeneca reported that it has completed the divestment of its 26.7% ownership in Viela Bio, Inc. (Viela), as part of the proposed acquisition of Viela by Horizon Therapeutics plc (Press release, AstraZeneca, MAR 16, 2021, View Source [SID1234576702]). This follows the agreement to divest the shareholding on 1 February 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial considerations
AstraZeneca has received cash proceeds and profit of c.$775m. This will be accounted for in other operating income in the Company’s financial statements. The divestment does not impact the Company’s financial guidance for 2021.